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Abstract
Background: Concerns about worsening memory (‘‘memory concerns’’; MC) and impairment in memory performance are
both predictors of Alzheimer’s dementia (AD). The relationship of both in dementia prediction at the pre-dementia disease
stage, however, is not well explored. Refined understanding of the contribution of both MC and memory performance in
dementia prediction is crucial for defining at-risk populations. We examined the risk of incident AD by MC and memory
performance in patients with mild cognitive impairment (MCI).
Methods: We analyzed data of 417 MCI patients from a longitudinal multicenter observational study. Patients were
classified based on presence (n = 305) vs. absence (n = 112) of MC. Risk of incident AD was estimated with Cox Proportional-
Hazards regression models.
Results: Risk of incident AD was increased by MC (HR= 2.55, 95%CI: 1.33–4.89), lower memory performance (HR= 0.63,
95%CI: 0.56–0.71) and ApoE4-genotype (HR= 1.89, 95%CI: 1.18–3.02). An interaction effect between MC and memory
performance was observed. The predictive power of MC was greatest for patients with very mild memory impairment and
decreased with increasing memory impairment.
Conclusions: Our data suggest that the power of MC as a predictor of future dementia at the MCI stage varies with the
patients’ level of cognitive impairment. While MC are predictive at early stage MCI, their predictive value at more advanced
stages of MCI is reduced. This suggests that loss of insight related to AD may occur at the late stage of MCI.
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Introduction
The syndrome of mild cognitive impairment [1] (MCI) has been
established as a risk state for Alzheimer’s Dementia (AD). Patients
with MCI show cognitive impairment objectified by neuropsy-
chological testing while their functional activities are largely intact.
In addition, current criteria for MCI [1–3] require report on
cognitive decline, provided either by the patient and/or by an
informant or clinician who knows the patient well.
Compared to the current knowledge and standards of neuro-
psychological testing, the criterion of subjective report about
cognitive decline in the definition of MCI is less elaborated. It is
unknown whether more precise operationalization (either quan-
titatively or qualitatively) of this criterion may increase the
predictive accuracy for AD in MCI patients. In fact, in everyday
clinical practice, the criterion of experienced or observed cognitive
decline might often be considered fulfilled by the fact that a patient
consults the medical system for diagnostic workup of cognitive
impairment. Studies that investigated the role of individual and
informant reports for the prediction of AD in MCI are rare. One
early study [4] found informant reports but not the individual’s
memory complaints associated with future AD in memory
impaired patients. A recent study [5] in a non-demented elderly
community sample found both self and informant reports to be
predictive, while in a combined predictive model only informant
reports together with neuropsychological tests remained a
significant predictor.
Other studies, based on pre-MCI samples, showed elevated risk
of future AD [6–8] as well as associations with biomarkers of
Alzheimer’s disease in individuals who report self-experienced
cognitive decline [9–15]. However, there are also studies that did
not find associations of self-reported cognitive decline with either
incident AD [16] or biomarkers of Alzheimer’s disease [17,18] in
pre-MCI samples. Importantly, comparability of results across
studies is limited due to heterogeneity of samples and assessment of
self-experienced cognitive decline. Further, it was recently
reported that, in individuals with normal cognitive test perfor-
mance (non-MCI), those who are particularly concerned about
their experienced memory decline have a higher risk of developing
AD, as compared to those who report a self-experienced memory
decline without concerns [19,20]. Thus, the appraisal of the
experienced decline as worrying may be of specific predictive value
when assessing an individual’s report.
Based on the existing data, the significance of self-reported
concerns about worsening memory (hereafter: ‘‘memory con-
cerns’’ (MC)) in MCI is yet unclear and it is largely unknown what
factors might influence the report or denial of MC in MCI patients
[21,22]. Reduced self-awareness is one factor that might influence
the report of MC in this patient group [22]. Self-awareness often
becomes impaired during the progression of Alzheimer’s disease.
Hence, unawareness (also termed anosognosia) concerning the
memory impairment is frequently observed in AD [23]. Reduced
self-awareness and anosognosia are also observed in MCI patients
[23–25]. However, levels of awareness are heterogeneous among
these patients [22]. This might contribute to the fact that MC are
not consistently present in patients with MCI [23,24,26].
The heterogeneity in self-awareness may originate from the fact
that anosognosia as a core symptom of AD manifests at the stage of
MCI and that the likelihood of its occurrence rises with increasing
cognitive impairment. Evidence for this assumption comes from
studies that investigated self-awareness in patients with AD and
patients with amnestic MCI (i.e. with clinical impairment in the
memory domain, evidenced by neuropsychological testing [1,2]).
Patients with advanced amnestic MCI, scoring lower than two
standard deviations (SD) below age-corrected norms on a memory
test [24], showed symptoms of anosognosia similarly severe
compared to the AD group. In a study on amnestic MCI patients,
Nobili and colleagues found that low awareness of memory deficits
was associated with more progressed Alzheimer’s disease pathology
[27]. Moreover, results from a recent study showed that cognitive
complaints decreased with decreasing cognitive performance in
MCI patients, while the relationship was opposite (i.e. reported
complaints increased with decreasing memory performance) in
individuals with only subjective memory impairment but no MCI
[18]. These results suggest that, within the stage of MCI, those
patients with more severe cognitive impairment tend to have
reduced insight into their cognitive deficits.
Based on the empirical evidence a hypothetical model of AD
prediction in MCI can be formulated: At the earliest stage of
impairment (early MCI) self-awareness of the patient is mostly
unaffected. Here, MC should reflect the true self-perceived,
longitudinal intra-individual decline and should contribute to AD
prediction in addition to cross-sectional impairment on tests. At
later stages of MCI, self-awareness is waning and the predictive
value of MC is declining. MC as defined in this model comprises
two important aspects, i.e. the specific notion of (1) a decline in
memory performance and (2) the appraisal of this self-perceived
decline as worrying. The appraisal as worrying extends beyond the
subjective report about cognitive decline as part of the general
MCI criteria and has been found to be of higher predictive value
than the notion of a worsening memory without worries [19,20].
This clearly separates the definition of memory concerns in our
study from subjective memory decline in general.
In the present study, we tested the proposed model in a sample
of MCI patients whose memory impairment ranged from very
mild to advanced severity.
Methods
Ethics statement
The protocol of the study was approved by the Institutional
Review Board (IRB) of the Medical Faculty, University of
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Erlangen (coordinating study center) and by IRBs at each
individual participating study center, listed in the following: IRB
Medical Faculty, University of Hamburg; IRB Charite´ –
University Medicine Berlin; IRB Medical Faculty, University of
Go¨ttingen; IRB Medical Faculty, University of Du¨sseldorf; IRB
Medical Faculty, University of Bonn; IRB Medical Faculty,
University of Leipzig; IRB Medical Faculty, University of
Frankfurt (am Main); IRB Medical Faculty, University of
Heidelberg; IRB Medical Faculty, Saarland University; IRB
Medical Faculty, University of Mannheim; IRB Medical Faculty,
University of Freiburg; IRB Medical Faculty, Ludwig Maximilian
University Munich; IRB Medical Faculty, Technical University
Munich.
The study was conducted in accordance with the Declaration of
Helsinki. After complete description of the study to the patients,
written informed consent was obtained.
Participants
Subjects were recruited between 2003 and 2007 at 14
specialized university memory clinics collaborating within the
German Dementia Competence Network (DCN). The general
procedures for assessment and selection of subjects have been
reported in detail previously [28]. Briefly, patients over 50 years of
age who were referred to or sought help at one of the participating
memory clinics underwent a clinical, neuropsychological and
laboratory assessment and brain imaging. Patients with either
MCI or mild dementia were asked to participate in this
longitudinal observational study.
Clinical and neuropsychological assessment
Patients were assessed annually by experienced physicians and
neuropsychologists for up to three years with standardized
diagnostic procedures as described in detail previously [28]. This
assessment included the neuropsychological test battery of the
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD-NP) [29]. The CERAD-NP consists of various subtests,
including the Mini Mental State Examination (MMSE) [30], and
is specifically designed to assess the cognitive domains most
commonly affected in AD. The subtests are (in order of
administration) (1) Verbal Fluency, (2) modified Boston Naming
Test (15 item version), (3) the MMSE, (4) Word List Learning of a
10-item word list (sum of three learning trials; maximum score of
30), (5) Figure Copying (maximum score of 11), (6) Word List
Delayed Recall (maximum score of 10), (7) Word List Recognition
(maximum score of 10 or 100%), and (8) Figure Recall (maximum
score of 11). We used the Word List Delayed Recall subtest
(CERAD-DR) as a measure of objective memory impairment as
delayed recall of word lists is considered among the tests that are
most sensitive to incipient AD [3]. In addition, high levels of
diagnostic accuracy for the CERAD-DR have been reported
regarding cross-sectional detection [31] and prediction of AD [32].
Depressive symptoms were rated by the interviewer with the
Montgomery Asberg Depression Rating Scale (MADRS) [33].
The MADRS consists of 10 items which are scored from 0 to 6
after a clinical interview. It is well established in psychogeriatric
and AD studies [34]. A cut-off score of 13 points is suggested for
mild depression. Instrumental activities of daily living were
assessed with the Bayer-Activities of Daily Living Scale (BADL),
a 25-item, informant-rated questionnaire developed to assess
deficits in the performance of everyday activities in patients with
MCI or mild-to-moderate dementia [35].
Definition of MCI and incident AD
All diagnoses were established in a consensus conference
between physicians and neuropsychologists at each site. The
diagnosis of MCI was made according to the consensus criteria
proposed in 2004 by the International Working Group on MCI
[2]: (1) subjective and/or informant report about cognitive decline,
(2) evidence of an impairment on objective cognitive test, (3) no or
only minor impairments in instrumental activities of daily living
(BADL score ,4), and (4) not demented. Criterion (2) was met if
patients showed a cognitive deficit of more than 1SD below age-
and education-adjusted norms in at least one subtest of the
CERAD-NP battery or in the Wechsler-Memory-Scales Logical
Memory II subtest. The diagnosis of incident AD was made
according to the NINCDS/ADRDA criteria for probable
Alzheimer’s disease [36].
Classification of participants into ‘‘MCI with memory
concerns’’ vs. ‘‘MCI without memory concerns’’
Patients were classified as ‘‘MCI with memory concerns’’ (MC+)
or ‘‘MCI without memory concerns’’ (MC-) according to their
response to the following standardized question [6]: ‘‘Do you feel
like your memory has become worse’’. Possible answers were: (1)
‘‘No’’, (2) ‘‘Sometimes, but this does not worry me’’, (3) ‘‘Yes, that
worries me’’, (4) ‘‘Yes, that worries me seriously’’. Answers (1) and
(2) were combined to the MC- and answers (3) and (4) to the MC+
group, respectively.
The question and response categories were read aloud to
patients by the interviewer as part of the initial assessment prior to
neuropsychological testing. Duration of MC was not assessed in
this study.
The standardized question on memory concerns was not used
for the initial diagnosis of MCI but only for division into groups of
MC+ and MC- patients respectively. The criterion of subjective
report on cognitive decline required for the diagnosis of MCI
could be provided either by the subject and/or by an informant
according to the criteria of the International Working Group on
MCI [2]. Thus the MC+ group constitutes a subgroup of MCI
patients who themselves, when questioned in person with a
standardized item, report memory decline which they appraise as
particularly worrying. MC as operationalized here thus extend
beyond the subjective report about cognitive decline as part of the
general MCI criteria. Patients in the second response category
‘‘sometimes, but this does not worry me’’ were therefore assigned
to the MC- group. We also refrained from keeping the four
categories separate as this would have prevented the detailed
analysis and straightforward interpretation of moderating effects
between categorical (MC+ vs. MC-) and continuous (memory
performance) variables, also due to limited number of participants
answering ‘‘No’’ to the question on experienced memory decline.
However, we report descriptive statistics of interest (conversion
rates and memory performance) for all subgroups.
Statistical analysis
Differences between groups were evaluated using independent
sample t-tests for continuous and Chi2-test for categorical
variables, respectively. Risk of incident AD was evaluated using
stepwise Cox Proportional-Hazards regression analyses (SPSS-
Version-20). Hazard Ratios (HR) with corresponding 95%
Confidence Intervals (CI) are reported. Continuous predictors
were age, years of education and the CERAD-NP delayed recall
score (CERAD-DR). These were mean-centred prior to analysis
by subtracting the respective sample mean from each observed
value. Categorical predictors were gender, ApoE4-status (no E4
Memory Concerns and Dementia Risk in MCI Patients
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allele vs. presence of one or two E4 alleles) and group-status (MC-
vs. MC+ group). In step 1 we entered age, gender, education,
ApoE4 plus the CERAD-DR in the model. In step 2 we added
group-status as an additional variable, to test the hypothesis that
MC contribute to the risk of incident AD over time after
controlling for objective memory impairment. In step 3 we added
the linear interaction term of group-status and memory perfor-
mance (group-status*CERAD-DR) to the model to test the
hypothesis that the impact of MC on risk of future AD is
moderated by the level of objective memory impairment. In an
additional analysis we added the MADRS score in step 1 to
control for depressive symptoms as a possible confounder.
Eight hundred and thirteen MCI patients were included at
baseline in the longitudinal observational study. For the present
analyses we included patients with a MMSE score between 24 and
30 (inclusive) and excluded patients with incomplete clinical or
neuropsychological data required for the classification of sub-
groups and for statistical analysis. We further excluded those
without information on ApoE4 genotype and those who withdrew
early from the study without at least one follow-up visit at 12
months after baseline. Application of these criteria resulted in a
sample of 454 MCI patients eligible for the present analyses.
Thirty-seven patients (8.1%) converted to dementia other than AD
during follow-up. We excluded these cases for the present analysis
as our focus was on the impact of MC on incident AD. The final
sample had a size of n= 417 MCI patients. Dropout analysis
revealed that the group of patients excluded due to missing
baseline data or lack of follow-up were older on average
(Mexcluded = 68.8, SD=8.73; Mincluded = 65.6, SD=7.93; p,0.05)
but had only slightly lower MMSE mean scores (Mexcluded = 27.3,
SD=1.72; Mincluded = 27.7, SD=1.66; p,0.05). The two groups
did not differ regarding years of education, gender distribution and
expression of memory concerns (i.e. distribution of MC+ vs. MC-).
Results
Descriptive statistics of the sample
Of the 417 included patients, 19 patients (4.6%) responded
‘‘No’’ to the question on experienced memory decline, 93 (22.3%)
answered ‘‘Sometimes, but this does not worry me’’, 211 (50.6%)
answered ‘‘Yes, that worries me’’ and 94 (22.5%) answered ‘‘Yes,
that worries me seriously’’. Thus, 112 (26.9%) patients were
classified as MC- and 305 (73.1%) as MC+. The two groups did
not differ in demographical variables, frequency of ApoE4 status,
MMSE score, memory- or overall cognitive impairment on the
CERAD-NP and mean follow-up time. MC+ patients showed
higher scores on the MADRS scale and slightly higher BADL
scores (Table 1).
Risk of AD
Seventy-four patients (17.7%) developed incident AD within a
mean follow-up time of 27.6 months. The incidence rate differed
significantly between groups (9.8% vs. 20.7% for the MC- and
MC+ group respectively). Incidence rates according to the
individual response categories of the question on experienced
memory decline were 6 out of 19 (31.6%) in the ‘‘No’’ category, 5
out of 93 (5.4%) in the category ‘‘Sometimes, but this does not
worry me’’, 42 out of 211 (19.9%) in the category ‘‘Yes, that
worries me’’, and 21 out of 94 (22.3%) in the category ‘‘Yes, that
worries me seriously’’. With regard to memory performance, the
patients answering ‘‘No’’ had the lowest mean CERAD-DR scores
(M=4.37, SD=2.63) while patients in the other categories
displayed better and similar mean CERAD-DR scores (category
‘‘Sometimes, but this does not worry me’’: M=5.48, SD=2.01;
category ‘‘Yes, that worries me’’: M=5.29, SD=2.16; category
‘‘Yes, that worries me seriously’’: M=5.53, SD=2.21). Mean
CERAD-DR performance in the group of patients answering
‘‘No’’ was significantly lower compared to that of patients in the
other three response categories (t = 1.99, df = 415, p = 0.048).
Table 1. Description of the sample.
Total Sample (n =417
MCI patients)
MC- group (n =112
MCI patients)
MC+ group (n =305
MCI patients) MC- vs. MC+ group
Cohen’s d p-value
Age (M, SD) 65.6 (7.93) 66.3 (8.70) 65.4 (7.63) 0.11 0.341
Years of Education (M, SD) 12.6 (2.84) 12.8 (2.81) 12.5 (2.85) 0.12 0.270
MMSE-Score (M, SD) 27.6 (1.66) 27.6 (1.62) 27.7 (1.67) 20.06 0.617
CERAD Delayed Recall (M, SD) 5.3 (2.21) 5.3 (2.15) 5.4 (2.23) 20.03 0.766
CERAD Total Score (M, SD) 73.3 (10.8) 73.4 (10.9) 73.2 (10.7) 0.02 0.888
MADRS (M, SD) 7.93 (6.34) 5.13 (5.01) 8.95 (6.47) 20.63 ,0.001
BADL-Score (M, SD) 2.16 (1.29) 1.96 (1.37) 2.23 (1.26) 20.21 0.061
Follow-Up time in months (M, SD) 27.6 (9.85) 28.5 (10.5) 27.3 (9.61) 0.12 0.304
Time to Conversion in months (M, SD) 19.1 (7.80) 20.8 (7.42) 18.8 (7.87) 0.27 0.422
Chi2 p-value
Female gender (n, %) 170 (40.8) 42 (37.5) 128 (42.0) 0.68 0.411
Positive ApoE4-status (n, %) 158 (37.9) 44 (39.3) 114 (37.4) 0.13 0.722
Conversion to AD (n, %) 74 (17.7) 11 (9.8) 63 (20.7) 6.59 0.01
Note. P-values are derived from independent sample t-tests (2-sided) for comparison of continuous variables, and from Chi2-tests for categorical variables. AD =
Alzheimer’s Dementia, BADL = Bayer-Activities of Daily Living Scale, CERAD = Consortium to Establish a Registry for Alzheimer’s Disease, M = Mean, MADRS =
Montgomery Asberg Depression Rating Scale, MMSE = Mini-Mental-State-Examination, MCI = Mild Cognitive Impairment, MC- = MCI patients without Memory
Concerns, MC+ = MCI patients with Memory Concerns, SD = Standard deviation.
doi:10.1371/journal.pone.0100812.t001
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Results of the Cox Proportional-Hazards regression models are
presented in Table 2. In step 1, positive ApoE4 status (HR=1.89,
95% CI: 1.18–3.02) and lower CERAD-DR performance
(HR=0.63, 95% CI: 0.56–0.71) were associated with higher risk
of developing incident AD, yielding acceptable model fit
(Nagelkerkes R2= 0.262).
Group-status (MC- vs. MC+) was entered in step 2 of the
analysis. In addition to CERAD-DR and ApoE4, presence of MC
(i.e. belonging to the MC+ group) was also associated with an
increased risk of future AD (HR=2.55, 95% CI: 1.33–4.89) and
significantly increased model fit (D-Chi2 = 9.5, df = 1, p = 0.002,
change in Nagelkerke’s R2 = 2.1%). Thus, the hypothesis that
presence of MC does individually contribute to the risk of future
AD after controlling for objective memory impairment, was
supported by the results of the regression analyses.
The third step of the regression model included the interaction
term of group-status and CERAD-DR. The overall model fit was
again improved by inclusion of the interaction term (D-Chi2 = 4.8,
df = 1, p= 0.028, change in Nagelkerke’s R2 = 1%), supporting the
hypothesis that the impact of MC on risk of future AD varies with
the severity of objective memory impairment. The HR-value of
the interaction term is greater than one (HR=1.51, 95% CI:
1.01–2.25), which means that the impact of MC on the risk of
future AD increases with higher memory performance and
decreases with lower memory performance with an estimated
factor of 1.5 per word. This moderating effect is depicted in
Figure 1 (black solid line) where on the Y axis the estimated HR of
MC is plotted as a function of memory performance (CERAD-
DR). As can be seen here, the HR of MC decreases with
decreasing memory performance, i.e. when moving from left to
right along the X axis.
The additional analysis with the MADRS score as a predictor
added in step 1 of the modelling process revealed that depressive
symptoms were not associated with risk of future AD (p= 0.56)
and did not alter the results reported above.
Discussion
In the present study we found that MC, which extend beyond
the subjectively experienced memory decline that is part of the
general MCI criteria set, were associated with an increased risk of
incident AD. This main effect of MC is of importance as it suggests
that reported concerns regarding self-perceived memory decline
(rather than just self-report without associated concerns) are
predictive for future AD in the MCI stage. We suggest that the
magnitude of this main effect (about two-fold increased risk in the
MC+ group) is of clinical relevance. Our findings are in line with
results from an independent population-based study which found
that self-perceived memory decline with reported concerns is
associated with a higher risk of incident AD than the mere notion
of worsening memory (without concerns) [19,20]. These results
also suggest that AD related memory decline might be experienced
in a different quality (i.e. as more serious and therefore worrying)
compared to memory decline related to other factors such as
normal aging. As an alternative hypothesis, proneness to
psychological distress, a trait which has been reported as a risk
factor for AD [37], might also be associated with a higher
proneness to worry about self-perceived memory decline. If true,
this could also explain the higher risk of incident AD associated
with endorsing worries about worsening memory. We also stress
that the main effect of MC does not imply that MCI patients
without concerns about worsening memory are of no risk of future
AD, but our data suggest that their risk is lower at a group level.
Interestingly, in the small patient group who answered ‘‘No’’ to the
question on experienced memory decline the conversion rate was
highest and the memory performance level was lowest.
We also observed an interaction effect between MC and
objective memory performance. The impact of MC on risk of
future AD was highest for patients with very mild memory
impairment and decreased with increasing memory impairment.
Compared to the main effect of MC, this interaction effect was less
strong. While this impedes a direct clinical applicability (e.g. for
prediction in the individual case), it still highlights that at a group
level MC and objective memory impairment interact in the course
of AD. We suggest that this interaction between MC and memory
performance is meaningful in several ways. Firstly, at the stage of
very mild memory impairment, the assessment of self-perceived
and worrying intra-individual decline might further contribute to
AD prediction in addition to cross-sectional impairment on tests.
This is of relevance as it highlights the particular value of self-
reported memory decline with associated worries at the stage of
very mild impairment [20].
Secondly, the effect of decreasing predictive validity of MC with
increasing memory impairment may be caused by the reduction of
self-perceived insight into symptoms at later stages of MCI. In this
regard, we observed the highest conversion rate (31.6%) in the
group answering ‘‘No’’ to the MC question, i.e. in those patients
who were neither concerned about worsening memory nor
reported any experienced memory decline at all. These patients
also had the lowest CERAD-DR performance in the studied
sample which is consistent with this potential explanation. Our
observation is in line with results from a recent brain 18F-FDG-
PET imaging study in a sample of single- and multidomain
amnestic MCI patients (memory performance of ,1.5 SD below
norm), which also included an assessment of awareness [27].
Figure 1. The impact of memory concerns on the risk of future
Alzheimer’s Dementia is moderated by objective memory
performance at baseline. Note. The impact of memory concerns
on the risk of future Alzheimer’s Dementia, expressed in terms of the
Hazard Ratio (HR) for the predictor ‘‘memory concerns’’, is plotted as a
function of objective memory performance at baseline, i.e. the
interaction effect between memory concerns and objective memory
performance is depicted. Values are derived from the multivariate Cox-
proportional Hazard Regression analysis (see Table 2, model step 3: HR
of the interaction-term =1.51, 95% Confidence Interval: 1.01–2.25). The
black solid line corresponds to the estimated HR-value = 1.51 of the
interaction effect. The two dotted lines represent the functional curves
that result when the boundary HR-values of the lower 95% Confidence
Interval ( = 1.01) or upper 95% Confidence Interval ( = 2.25) respectively,
are inserted as numbers to plot the interaction effect. CERAD-DR =
Delayed Recall of the Consortium to Establish a Registry for Alzheimer’s
Disease Neuropsychological Assessment Battery.
doi:10.1371/journal.pone.0100812.g001
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2SD below norm). They found similar levels of reduced awareness
for this MCI group compared to a group of AD patients and
observed lower MMSE scores to be associated with lower levels of
awareness. Furthermore, one recent study has shown that, in the
group of MCI patients, subjective cognitive complaints decreased
with increasing cognitive impairment [18]. Based on these
empirical data, we propose that anosognosia, which is a well-
known clinical sign of AD, might occur at the stage of late MCI. At
the stage of very mild MCI, before this loss of valid self-perception,
the presence of MC is predictive of future AD. This is in
agreement with several studies showing that subjective memory
decline in individuals with normal cognitive function is also
predictive for AD [6–8;19,20].
Depressive symptoms did not predict risk of future AD in the
present study and inclusion of depressive symptoms as a possible
confounding variable did not alter the effects for objective memory
impairment and MC. It is important to note, that although the
MC+ group scored higher on the MADRS, their mean MADRS
score reflected only very mild depressive symptoms and did not
correspond to the clinical diagnosis of a major depression. ApoE4
status was associated with a higher risk of incident AD which is in
line with recent studies [38,39]. However, frequencies of ApoE4
did not differ between the MC+ and MC- group. Results remained
similar when ApoE4 was not accounted for in the models and we
did not observe an interaction between MC and ApoE4 with
regard to risk of incident AD in additional post-hoc analyses (data
not shown). ApoE4 and MC thus independently contributed to
risk of AD in the present sample. We also controlled for level of
education in our analysis. Regarding the interplay of education
and memory concerns, results from a large population based
cohort study of non-demented elderly suggest that the clinical
relevance of subjective memory complaints might be higher in
individuals with higher educational background [40]. We also
tested for an interaction between memory concerns and level of
education in our analysis but did not find such an effect (data not
shown). Differences in samples and design (i.e. community based
cohort of non-demented elderly vs. memory clinic MCI sample in
our study) might have contributed to these discrepant findings.
Our results are different to those of other studies which did not
find a clear association between self-reports of memory decline
and incident AD [4,5]. However, besides differences regarding
samples and assessment of self-reported memory decline, these
studies did also include informant reports in their predictive
models. Therefore the comparability of our results to these studies
is limited and we acknowledge the lack of informant reports in our
study as a limitation.
A strength of the present study is the large number of
neuropsychologically well characterized patients who met criteria
for MCI [2]. Within these criteria we set the cutoff for cognitive
impairment at 1SD below the normative mean. This procedure is
in line with recently established study protocols of large studies,
e.g. ADNI-2 where recruitment was extended to early (amnestic)
MCI patients with very mild memory impairment (,1.0 SD below
the norm) [41]. The present sample therefore enabled us to test the
specific contribution of MC for risk of AD at different stages of
memory impairment within the MCI spectrum.
This study has limitations. The present sample reflects MCI
patients with at least very mild impairment in one cognitive
domain. Therefore the present results concerning the prognostic
value of MC at different levels of memory impairment only refer to
the MCI spectrum and not to cognitively unimpaired individuals.
Secondly, we focused on memory concerns only (rather than
concerns about other cognitive domains or cognition in general)
and on AD as the outcome. It is important to note that other
cognitive domains beyond memory can also be affected in MCI
due to Alzheimer’s disease [3]. Thirdly, data on duration of MC
and on discrepancies between the informant and the patient
regarding the report of MC was not available to us. Finally, our
sample reflects a memory clinic population and the transfer to
population-based cohort or volunteer samples may not be valid.
Dropout analysis also revealed that the patients included in this
study were three years younger on average compared to those
excluded due to baseline missing data or lack of follow-up.
However the two groups differed only slightly regarding baseline
cognitive functioning and, more importantly, the groups did not
differ in the expression of MC (73.1%MC+ in the study sample vs.
74.8% MC+ in those excluded from the analysis; p = 0.661). Thus,
although a small selection bias was observed in our data, we
consider the main results of our study not confounded by this bias.
In conclusion, the present study highlights a dynamic of the
impact of MC as a predictor for incident AD in MCI patients. The
results may have implications for clinicians working with elderly
patients at risk of AD, but also for the design of early intervention
trials in Alzheimer’s disease. MC should be taken seriously as a risk
indicator for future AD, especially in cases where neuropsycho-
logical test results are at the border between normal and impaired.
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